Received: 9 May 2022 | Revised: 8 September 2022 | Accepted: 13 September 2022
DOI: 10.1111/bcp.15545

ORIGINAL ARTICLE

BJCP BRITISH PHARMACOLOGICAL SOCIETY

Bioavailability and cardiovascular effects of adrenaline administered by Anapen 500 μg auto-injector in healthy volunteers

Thierry Duvauchelle[1] | Philippe Robert[2] | Yves Donazzolo[3] | Sabrina Loyau[4] | Bernard Orlandini[4] | Philippe Lehert[5,6] | Jeanne-Marie Lecomte[1] | Jean-Charles Schwartz[1]



[1]Bioprojet Pharma, Paris, France
[2]Bioprojet Biotech, Saint Gregoire, France
[3]Eurofins Optimed, Gières, France
[4]PhinC Development, Massy, France
[5]Faculty of Economics, University of Louvain, Louvain, Belgium
[6]Faculty of Medicine, University of Melbourne, Melbourne, Victoria, Australia

Correspondence
Thierry Duvauchelle, Bioprojet Pharma, 9 rue Rameau, 75002 Paris, France.
Email: t.duvauchelle@bioprojet.com

Funding information
This work was funded by Bioprojet Pharma, Paris, France.

Aims: Anaphylaxis guidelines recommend intramuscular adrenaline, commonly 300 μg administered using an auto-injector device. However, overweight/obese patients may require a higher adrenaline dose for adequate cardiovascular (CV) response. This study evaluated the pharmacokinetics (PK) and pharmacodynamic (PD) CV profiles after a single 500 μg adrenaline injection via Anapen auto-injector in healthy normal weight males and otherwise healthy, overweight or obese females.

Methods: In this exploratory open-label, single-centre study, 54 healthy volunteers aged 18-50 years received a single 500 μg adrenaline injection (Anapen auto-injector) in the thigh (antero-lateral middle third [18 males] or antero-inferior third [36 females]). Assessments included depot depth (ultrasonography), plasma adrenaline levels (liquid chromatography-tandem mass spectrometry) and heart rate (HR; ECG Holter monitor).

Results: Ultrasonography showed that 82.4% of normal weight males received intramuscular injections; all overweight and obese females received subcutaneous injections. Anapen injection produced rapid increases in circulating adrenaline levels and significant increases in systolic blood pressure (SBP) and HR. Second peak plasma adrenaline concentrations (C_{max2}) were reduced, and time to C_{max2} increased in overweight and obese females compared with males with normal body mass index; area under the curve (0–240 min) ($AUC_{(0\text{-}240)}$) was increased in overweight and obese females. Obese females had reduced maximal SBP values compared with normal weight males or overweight females; overweight and obese females had markedly different HR time courses compared with normal weight males.

Conclusion: A 500 μg adrenaline injection via Anapen produced rapid PK/PD changes in normal weight, overweight and obese subjects, irrespective of intramuscular or subcutaneous injection, and was well tolerated.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2022 Bioprojet Pharma. *British Journal of Clinical Pharmacology* published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

KEYWORDS
adrenaline, Anapen, anaphylaxis, auto-injector, cardiovascular responses, pharmacodynamic, pharmacokinetic

1 | INTRODUCTION

Anaphylaxis is a serious, potentially fatal, allergic reaction commonly triggered by food, insect venom or medicinal drugs.[1–5] Guidelines recommend intramuscular adrenaline as first-line therapy for anaphylaxis.[6–9] An early randomized controlled pharmacokinetic (PK) trial in healthy volunteer adults demonstrated that intramuscular injection of adrenaline into the thigh was the preferred route of administration. This was achieved using either an auto-injector or ampoule-based injection using a needle and syringe.[10] Adrenaline administration by auto-injector is the preferred method of treating anaphylaxis in the community, particularly in individuals who are at risk for severe anaphylaxis.[11,12] However, after a procedure following Article 31, the European Medicines Agency requested all companies marketing adrenaline auto-injectors in the European Union to implement PK/pharmacodynamic (PD) clinical studies to assess the relevance of their devices.

A recent PK and PD study which compared the Anapen auto-injector device (10 mm ± 1.5 mm needle length; Bioprojet Pharma, Paris, France) with a prefilled syringe with a 25.4-mm needle to administer adrenaline to healthy adult volunteers, at the most common dosage (300 μg), showed that needle length and intramuscular injection are not absolute requirements for efficacy; it also demonstrated the biphasic PK and PD responses and underlined the importance of a precocious first peak in this life-threatening condition.[13] Comparison of PK profiles in normal weight men and overweight women treated with Anapen showed that the magnitude of the first peak of circulating adrenaline was similar, despite the injection being subcutaneous in the latter group.[13] However, the current adrenaline dose of 300 μg may not suffice for patients with body mass more than 50 kg, which may require a larger dose for adequate cardiovascular (CV) response.

In this exploratory study, we compare the local injection targeting, PK, PD CV and tolerance profiles of adrenaline after a single 500 μg injection in the thigh using an Anapen auto-injector in three different populations: normal healthy male volunteers, and otherwise healthy, overweight or obese female volunteers.

What is already known about this subject

- Anaphylaxis guidelines recommend intramuscular adrenaline, commonly 0.01 mg/kg (ie, 0.5 mg for a 50-kg patient) administered using an auto-injector device, as cornerstone therapy.
- However, overweight or obese patients may require a higher adrenaline dose for adequate cardiovascular response.

What this study adds

- A 500 μg adrenaline injection using the Anapen device produced rapid pharmacokinetic and pharmacodynamic cardiovascular changes in normal weight, overweight and obese healthy volunteers, irrespective of intramuscular or subcutaneous injection, and was well tolerated.
- While acknowledging potential generalizability limitations, combined assessment of ultrasonographic depot localization, plasma adrenaline levels and cardiovascular responses in normal weight, overweight and obese healthy volunteers allows the prediction of adrenaline auto-injector efficacy for anaphylaxis.

2 | METHODS

2.1 | Design

This was an open-label, single-centre, one-period study (EudraCT number: 2016-000269-22).

2.2 | Ethics statement

Study approval was given by an independent Ethics Committee Comite de Protection des Personnes of Sud-Est IV, Lyon, France and the French Regulatory Authority – Agence Nationale de Sécurité du Médicament et des Produits de Santé. The study was performed in accordance with Good Clinical Practice and the ethical principles stated in the Declaration of Helsinki.[14]

2.3 | Inclusion and exclusion criteria

Male or female healthy volunteers aged 18 to 50 years who were nonsmokers or light smokers (<5 cigarettes per day) were eligible. The study recruited healthy male normal weight volunteers with a body mass index (BMI) of 18-26 kg/m^2 and otherwise healthy, overweight (BMI > 26-34 kg/m^2) and obese (BMI > 34-42 kg/m^2) female volunteers. Each participant provided written informed consent.

13652125, 2023, 3, Downloaded from https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15545 by Cochrane France, Wiley Online Library on [26/02/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

The main exclusion criteria were as follows: clinically significant acute or chronic disease, including known or suspected HIV (HIV 1 or 2 antibodies), HBV (hepatitis B surface antigen [HbsAg]-positive) or HCV (HCV antibodies) infection; a history of allergy, allergic skin rash, asthma, intolerance, sensitivity or photosensitivity to any drug; clinically significant abnormality following review of prestudy laboratory tests, vital signs, full physical examination, cardiac echocardiography and cardiac stress test for males aged >35 years and females aged >40 years and electrocardiogram (ECG); pregnancy; suspected alcohol (>14 units of alcohol per week) or drug abuse (positive urine drug screening test for opiates, cocaine, amphetamine, barbiturates, cannabis, benzodiazepines); excessive caffeine consumption (>8 cups daily); surgery or blood donation within 12 weeks prior to the start of the study; taken any prescribed or over-the-counter drug (including antacids), with the exception of oral contraceptives, menopausal substitutive treatment and paracetamol (up to 3 g per day) within 2 weeks prior to treatment.

2.4 | Treatment

For 48 hours preceding treatment and up to the end of the study, subjects abstained from smoking and drinking alcohol, coffee, tea or beverages containing methylxanthines (ie, theophylline, caffeine or theobromine). Prior to administration, subjects fasted overnight for a minimum of 10 hours.

A single injection of adrenaline (500 μg) using the Anapen auto-injector device (needle length 10 mm ± 1.5 mm) was administered into the antero-lateral middle third of the thigh (male participants) or the antero-inferior third of the thigh (females).

2.5 | Objectives

The primary objective was to evaluate the PK and the PD CV profile of adrenaline after a single 500 μg injection in the thigh using an Anapen auto-injector in three different populations: normal healthy male volunteers, and otherwise healthy, overweight or obese female volunteers. Secondary objectives were to assess the local and general tolerability of adrenaline after a single 500 μg injection in the thigh using an Anapen auto-injector in the three different populations and to document the possibility of using ultrasound imaging to determine the injection depth.

2.6 | Ultrasonography

Ultrasound imaging of the injection site was performed pre-injection and postinjection to measure the distance between the upper skin layer and the *fascia lata* of the muscle and depth of drug depot, respectively. Skin-to-muscle distance was measured without pressure applied by the ultrasound probe.

2.7 | Pharmacokinetics

Blood samples were collected at −30, −20, −10, 1, 2, 4, 6, 8, 10, 12, 15, 20, 25, 30, 40, 50, 60, 90, 120, 150, 180 and 240 minutes postdosing. Plasma adrenaline concentrations were measured using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. PK parameters were derived using Phoenix WinNonlin software, v6.3 (Pharsight Corporation, Mountain View, CA, USA) using noncompartmental analysis. PK parameters for adrenaline determined were as follows: C_{max1} and C_{max2} (first and second peak plasma adrenaline concentrations, respectively), t_{max1} and t_{max2} (time to C_{max1} and C_{max2}, respectively), and area under the curve (AUC) parameters, $AUC_{0\text{-}20}$ and $AUC_{0\text{-}240}$.

2.8 | Pharmacodynamics

Systolic blood pressure (SBP), pulse rate and Holter ECG-calculated heart rate (HR) were recorded. Mean heart rate was evaluated by 1-minute time windows from 30 minutes predose to 2 hours postdose using a 12-lead 200 Hz Holter ECG. For SBP, the PD parameters determined were as follows: $E_{max0\text{-}20}$, $E_{max20\text{-}60}$, $E_{max60\text{-}240}$ (postdose maximum changes from baseline effect), $t_{Emax0\text{-}20}$, $t_{Emax20\text{-}60}$, $t_{Emax60\text{-}240}$ (time to E_{max}), and area under the effect curve (AUEC) parameters $AUEC_{0\text{-}20}$, $AUEC_{20\text{-}60}$, $AUEC_{60\text{-}240}$ and the proportion of responders. For HR, the same PD parameters were determined except $E_{max60\text{-}120}$, $t_{Emax60\text{-}120}$ and $AUEC_{60\text{-}120}$, which replaced the corresponding 60-240-minute parameters.

2.9 | Safety

The incidence of adverse events (AEs) and changes in physical examination, vital signs (blood pressure and HR), body weight, ECG, continuous cardiac rhythm monitoring and clinical laboratory tests between screening and the end of study were recorded.

2.10 | Statistical methods

All statistical analyses were conducted using SAS version 9.4. Categorical data were described using frequency and percentages, and continuous variables were described using the mean, standard deviation (SD), median, minimum, maximum and number of observations, and 95% confidence intervals (CIs) were calculated for changes from baseline.

No formal determination of sample size was done. Based on the literature, it was found that BP and HR changes further to adrenaline administration were of limited variability.[15] From this information, it was decided to allocate 18 subjects for each group. This sample size was deemed acceptable to allow a good evaluation of the impact of various doses of adrenaline on CV activity as well as an accurate determination of the PK/PD relationship.

13652125, 2023, 3, Downloaded from https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15545 by Cochrane France, Wiley Online Library on [26/02/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

E_{max} values calculated for SBP and HR were analysed using an analysis of covariance (ANCOVA) model using baseline value as a covariate and group as a fixed effect. Wilcoxon ranked sum tests were used for pairwise comparisons between groups on t_{Emax} variables. The proportion of responders defined by an increase in SBP ≥ 10 mmHg or an increase in HR ≥ 10 bpm on one or more occasion was analysed using a logistic model including group as a fixed effect.

PK and PD results were correlated using a linear model including age as a covariate for SBP *versus* C_{max} and a sigmoidal saturable E_{max} model for HR *versus* C_{max}.

3 | RESULTS

A total of 54 healthy subjects equally divided into three groups of 18 were enrolled in the study: male subjects with a mean (SD) age of 26.1 (4.3) years and a mean (SD) BMI of 23.3 (2.1) kg/m^2 (range 19.3-26 kg/m^2, Group 1), female subjects aged 30.3 (5.0) years with a mean (SD) BMI of 29.9 (2.1) kg/m^2 (range 26.7-33.3 kg/m^2, Group 2) and female subjects aged 32.8 (7.7) years with a mean (SD) BMI of 36.8 (2.1) kg/m^2 (range 34.1-41.7 kg/m^2, Group 3) (Table 1).

3.1 | Ultrasonography

The distance between skin and muscle (considered to correspond to skin thickness) and the depth of depot are summarized by group in Table 2. Mean skin thickness was 0.60 cm in Group 1 (normal weight males) but increased in obese subjects with mean values of 2.1 cm and 2.5 cm in Groups 2 (overweight females) and 3 (obese females), respectively. The maximum skin thickness observed was 4 cm.

Overall, most subjects in Group 1 received intramuscular injections, shown by a negative mean difference between skin thickness and depth of depot (−0.6) (Table 2). In 14 of 17 evaluable subjects (82.4%), values ranged from −0.47 to −1.14 cm, indicating intramuscular injection. However, in three subjects (17.6%) who had values between −0.09 (borderline) and 0.12 cm, injections were subcutaneous. A fluid depot was not visible in one Group 1 subject.

Mean differences between skin thickness and depth of depot in Groups 2 and 3 were 0.6 and 1.1, respectively, indicating subcutaneous injections (Table 2). In Group 2, values varied from −0.04 (borderline) to 1.58 cm, whereas the range in Group 3 was from 0.29 to 2.20 cm. A fluid depot was not visible in one Group 3 subject.

3.2 | Pharmacokinetics

Baseline measurement of plasma adrenaline concentrations was conducted at three time points 10 minutes apart (30, 20 and 10 minutes before injection). Most subjects had adrenaline concentrations below the limit of quantitation (39.1 pg/mL), but eight subjects (six in Group 1, one each in Groups 2 and 3) had quantifiable plasma adrenaline which was <10% of the C_{max} in seven subjects but more than 27% of C_{max} in one subject (baseline value 10 minutes before injection of 115.8 pg/mL). Consequently, PK analysis was performed on baseline-corrected concentration values for all subjects.

Adrenaline injection produced biphasic increases in mean plasma adrenaline concentrations over time in each group (Figure 1). In all groups, the first peak occurred within 15 minutes with median t_{max1} values for Groups 1, 2 and 3 of 0.23 hours (13.8 minutes), 0.23 hours (13.8 minutes) and 0.25 hours (15.0 minutes), respectively, which did not differ significantly (Table 3). The rank order of the timing of the second peak was the same with normal weight males (Group 1),

TABLE 1 Demographic data for Groups 1-3

	Group 1 (n = 18)	Group 2 (n = 18)	Group 3 (n = 18)
Sex	Male	Female	Female
Age (years), mean (SD)	26.1 (4.3)	30.3 (5.0)	32.8 (7.7)
Height (cm), mean (SD)	176.9 (6.1)	163.7 (6.6)	164.3 (5.7)
Weight (kg), mean (SD)	72.9 (6.8)	80.3 (8.4)	99.4 (7.5)
BMI (kg/m^2), mean (SD)	23.3 (2.1)	29.9 (2.1)	36.8 (2.1)

Note: All subjects were Caucasian with the exception of three individuals: one male in Group 1 and one female in Group 2 were Black, and one female in Group 2 was Hispanic.

TABLE 2 Ultrasonographic measurements of skin-to-muscle distance and depot depth in Groups 1-3

Group	Skin-to-muscle distance (cm)	Depot depth (cm)	Difference (cm)
Group 1	0.6 (0.2)	1.2 (0.2)	−0.6 (0.4)
Group 2	2.1 (0.5)	1.5 (0.2)	0.6 (0.4)
Group 3	2.5 (0.6)	1.4 (0.2)	1.1 (0.6)

Note: All data are presented as mean (SD); n = 18 for all measurements, except depot depth measurement in Groups 1 and 3 (n = 17).

13652125, 2023, 3, Downloaded from https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15545 by Cochrane France, Wiley Online Library on [26/02/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

having a median t_{max2} of 0.67 hours, equal with 0.67 hours in overweight females (Group 2) compared with 0.83 hours in obese females (Group 3) (Table 3). These equated to 40.2, 40.2 and 49.8 minutes, respectively, from the time of injection (T0).

C_{max2} values were higher than, or comparable with, the corresponding C_{max1} values (Table 3), as illustrated in the plasma adrenaline concentration time course graphs in Figure 1. In both overweight (Group 2) and obese (Group 3) females, the second peak was broader than that of normal weight males (Group 1), and mean C_{max2} values were lower in Groups 2 (580 pg/mL) and 3 (674 pg/mL) compared with Group 1 (740 pg/mL). Mean $AUC_{0\text{-}20}$ values were comparable in Groups 1, 2 and 3 (89, 97 and 65 h.pg/mL, respectively), whereas mean $AUC_{0\text{-}240}$ was higher in overweight (1133 h.pg/mL) and obese females (1390 h.pg/mL) compared with normal weight males (908 h.pg/mL) (Table 3). Adrenaline plasma concentrations in all groups did not return to basal levels within the 240-minute time period of the study (Figure 1).

3.3 | Pharmacodynamics

The time courses of mean change from baseline in SBP were comparable between groups, with a rapid increase within the first few minutes postinjection followed by a decrease and a secondary increase that lasted from about 6 to 60 minutes postdose (Figure 2). Maximum mean changes in SBP were observed at approximately 40 minutes in Group 1 (+10.4 mmHg), 20 minutes in Group 2 (+11 mmHg) and 60 minutes in Group 3 (+6.8 mmHg).

The time courses of mean changes from baseline in HR showed an increase from around 1 minute in all groups, but differences were apparent in profiles between normal weight males *versus* overweight or obese females (Figure 3). In Group 1, three main peaks (with fluctuations within each peak) were observed, but in Groups 2 and 3 there was less discrimination of peaks with effects prolonged, which could be linked to the higher bioavailability and AUC.

In all groups, adrenaline injection significantly increased SBP (Figure 2) and HR (Figure 3) from baseline irrespective of time interval (0-20, 20-60 or 60-240 minutes) ($P < .01$).

Pairwise comparisons of groups showed no significant differences for SBP- or HR-derived PD parameters E_{max} or t_{Emax}, as shown in Table 4.

PK/PD analysis showed that SBP and HR changes are directly related to circulating adrenaline concentrations with significant correlations ($P < .01$) irrespective of time interval (0-20, 20-60 or 60-240 minutes).

However, for Groups 2 and 3, a delay was observed from maximum mean C_{max2} (40-60 minutes postinjection) to a maximum change of HR (around 100 minutes).

The proportion of responders (defined as increases in SBP by ≥10 mmHg or HR by ≥10 bpm) was ≥88.9% in each group and varied depending on group and time interval. The response rates in Group 1, for 0-20, 20-60 and 60-240 minutes, were 94.4% (n = 17), 100% (n = 18) and 100% (n = 18), respectively. Respective response rates in Group 2 were 100% (n = 18), 100% (n = 18) and 88.9% (n = 16) and in Group 3 were 88.9% (n = 16), 94.4% (n = 17) and 100% (n = 18).



FIGURE 1 Time courses of mean adrenaline plasma concentrations after administration of 500 μg of adrenaline in Groups 1-3

3.4 | Safety

A total of 12 TEAEs were reported by nine subjects (16.7%) treated with 500 μg of adrenaline using the Anapen device. All TEAEs were of mild (five) or moderate (seven) intensity. No AEs of severe intensity nor serious adverse events (SAE) were reported during the study.

TABLE 3 Pharmacokinetic parameters for Groups 1-3 (n = 18 for each group)

Group	t_{max1} [a] (h)	C_{max1} (pg/mL)	t_{max2} [a] (h)	C_{max2} (pg/mL)	$AUC_{0\text{-}20}$ (h.pg/mL)	$AUC_{0\text{-}240}$ (h.pg/mL)
Group 1	0.225 [0.100, 0.333]	470 [306, 722]	0.667 [0.500 0.833]	740 [598, 916]	89 [58, 135]	908 [749, 1100]
Group 2	0.225 [0.167, 0.333]	541 [373, 783]	0.667 [0.458, 1.000]	580 [448, 752]	97 [65, 143]	1133 [944, 1360]
Group 3	0.250 [0.183, 0.333]	366 [217, 617]	0.833 [0.583, 1.000]	674 [551, 824]	65 [36, 116]	1390 [1187, 1629]

Note: Data are presented as geometric mean (95% CI) unless stated otherwise.
t_{max1} and C_{max1} are defined over the first 20-minute postdose interval; t_{max2} and C_{max2} are defined over the 20-240-minute postdose interval.
[a]Median [interquartile range] for t_{max} values.

13652125, 2023, 3, Downloaded from https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15545 by Cochrane France, Wiley Online Library on [26/02/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License



FIGURE 2 Time courses of mean change from baseline in systolic blood pressure (SBP) in Groups 1-3



FIGURE 3 Time courses of mean change from baseline in heart rate (HR) in Groups 1-3

All TEAEs were nervous system disorders, consisting of headache (eight events) and tremor (four events), and all were considered related to study product administration. These effects are known to occur in some people after adrenaline administration.

Injection-site reactions were common: Skin whitening was observed on one or more occasion in 29 subjects (53.7%), swelling was observed in two subjects (3.7%) and erythema in one subject (1.9%). Skin whitening is most likely related to localized vasoconstriction, while swelling is probably caused by the injection itself.

Some pre-existing individual abnormalities were recorded on laboratory parameters and ECG parameters. However, all these abnormalities were considered as nonclinically significant and reported in all groups.

3.5 | Comparison of PK data using Anapen 300 *versus* Anapen 500

Comparison of the current PK results with a PK study using Anapen 300 in healthy normal weight male and overweight female volunteers[13] showed that increasing the adrenaline dose from 300 to 500 µg (1.67-fold) produced increases in C_{max1}, C_{max2}, $AUC_{0\text{-}20}$ and $AUC_{0\text{-}240}$ by 1.70-, 2.21-, 1.69- and 2.10-fold, respectively, in normal weight male subjects (Table 5) and by 1.51-, 1.79-, 2.21- and 1.76-fold, respectively, in overweight females. Results in normal weight males showed that use of Anapen 500 (current study) in comparison with injection of 500 µg of adrenaline using a syringe equipped with a 1-in. (25-mm) needle (Group C; Duvauchelle et al.[13]) increased C_{max1}, C_{max2}, $AUC_{0\text{-}20}$ and $AUC_{0\text{-}240}$ by 1.6-, 1.5-, 1.5- and 1.2-fold, respectively. These results are consistent with previous results in normal weight males which showed significantly improved bioavailability (ie, increased maximum adrenaline concentration [C_{max1}, C_{max2}] and AUC [$AUC_{0\text{-}20 \text{ and }}$ $AUC_{0\text{-}240}$] with Anapen 300 compared with 300-µg adrenaline delivery with a prefilled syringe and a 1-in. needle).[13]

4 | DISCUSSION

This study investigated the PKs and PDs of a single 500 µg adrenaline injection using the Anapen auto-injector in healthy normal weight male and otherwise normal, overweight and obese female volunteers. Ultrasound scanning showed that most (89%) normal weight male subjects received intramuscular injections, whereas in all overweight or obese female subjects, injections were subcutaneous. Despite differences in the location of the adrenaline depot, the first peak of plasma adrenaline was still observed during the 0-20-minute window: t_{max1} was within 15 minutes postinjection in each group and C_{max1} values were comparable in the three groups. This is particularly important for counteracting the initial symptoms of anaphylactic shock, that is, the fall in BP and heart depression. Increases in plasma adrenaline levels were accompanied by rapid increases in SBP and HR.

Marked differences in the PKs and PDs between normal weight male and overweight or obese female subjects were observed during the 4-hour time course of the study, with differences in the location of the adrenaline depot likely to have a significant impact on results. Discrepant results included reduced C_{max2} and increased t_{max2} (within the 20-240-minute window) in overweight and obese female subjects compared with normal weight male subjects, reduced SBP E_{max} in obese female subjects compared with normal weight male or overweight female subjects and markedly different HR time courses in overweight and obese females compared with normal weight males.

In common with this study, the magnitude of the first peak (C_{max1}) following injection with 300 µg of adrenaline in normal weight men and overweight women was similar,[13] and also aligns with the overall peak magnitudes reported after administration of adrenaline via EpiPen (0.3 mg/mL) or intramuscular syringe (0.3 mg/mL) in healthy

13652125, 2023, 3, Downloaded from https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15545 by Cochrane France, Wiley Online Library on [26/02/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

TABLE 4 Mean (SD) systolic blood pressure- and heart rate-derived parameters over three time intervals (0-20, 20-60 and 60-240 minutes) in Groups 1-3

		Systolic blood pressure			Heart rate		
Time interval (min)	Group	E_{max} (mmHg)	t_{Emax} (min)	AUEC (mmHg/min)	E_{max} (beats)	t_{Emax} (min)	AUEC (beats/min)
0-20	1	16.6 (8.5)	10.5 (7.5)	166.2 (121.4)	20.7 (9.7)	9.1 (5.9)	120.7 (112.4)
	2	14.7 (6.1)	9.0 (6.7)	145.0 (101.8)	19.2 (7.1)	10.1 (5.4)	141.7 (114.3)
	3	11.9 (6.3)	6.2 (6.1)	60.8 (100.2)	17.9 (10.1)	11.3 (5.6)	103.6 (111.2)
20-60	1	17.7 (4.9)	37.2 (13.2)	427.1 (208.3)	22.1 (6.7)	39.2 (10.7)	355.7 (264.3)
	2	14.1 (5.3)	29.4 (10.8)	244.0 (240.2)	19.2 (7.7)	45.4 (12.2)	392.9 (273.0)
	3	11.7 (8.7)	40.0 (17.3)	163.9 (278.7)	18.3 (5.6)	41.6 (13.7)	373.2 (242.5)
60-240	1	12.2 (5.2)	101.7 (67.6)	380.8 (853.4)	21.6 (6.3)	81.1 (18.3)	270.6 (316.9)
	2	11.5 (8.4)	161.7 (72.1)	626.7 (987.5)	29.0 (14.1)	87.1 (18.9)	691.8 (485.9)
	3	13.1 (8.4)	118.3 (70.9)	448.3 (1021.1)	25.2 (7.2)	89.2 (19.9)	690.3 (425.8)

Note: E_{max} data represent changes (SD) from baseline.

TABLE 5 Comparison of PK data using Anapen 300[13] *versus* Anapen 500 (current study) in healthy normal weight males from two different studies

Dose (µg)	t_{max1}[a] (h)	C_{max1} (pg/mL)	t_{max2}[a] (h)	C_{max2} (pg/mL)	AUC_{0-20} (h.pg/mL)	AUC_{0-240} (h.pg/mL)
500	0.225 [0.100, 0.333]	470 [306, 722]	0.667 [0.500 0.833]	740 [598, 916]	89 [58, 135]	908 [749, 1100]
300	0.183 [0.167, 0.333]	294 [201, 429]	0.667 [0.417, 1.000]	335 [266, 423]	53 [35, 79]	439 [374, 516]
P-value	0.816	0.096	0.781	<0.001	0.071	<0.001

Note: Data are presented as geometric mean (95% CI) unless stated otherwise.
t_{max1} and C_{max1} are defined over the first 20-minute postdose interval; t_{max2} and C_{max2} are defined over the 20-240-minute postdose interval.
For each endpoint, we tested the significance of the difference by using one-way ANOVA on geometric means for all the endpoints, except Kruskal-Wallis test for t_{max1} and t_{max2}.
[a]Median [interquartile range] for t_{max} values.

volunteers across a wide range of skin-to-muscle-distances.[16] The present study also included obese women, who displayed slightly lower mean C_{max1} values than normal weight men and overweight women although there was considerable variance in the groups.

Tolerability after 500 µg adrenaline injection using the Anapen device was good, with headache and tremor that were mild or moderate in intensity being the most commonly reported TEAEs. These effects are known following adrenaline administration.[17] Compared with the 300-µg adrenaline injection, there was a nearly proportional increase in responses that was well tolerated, indicating that the dose increase should result in an enhanced efficacy associated with similar tolerance. This pattern should offer a valuable alternative in overweight or obese patients.

The current open-label study has some limitations, with a key limitation being that the study did not include cross-over with Anapen 300 in the same individuals (although this was not a study objective and was not requested by regulatory authorities). Another limitation is the fact that data obtained in healthy volunteers cannot be readily extrapolated and generalized to individuals in the general population who are in a stage of anaphylaxis; however, for the latter, this kind of study is impossible for ethical and practical reasons. In addition, the effects of a single 500 µg adrenaline injection were only evaluated in healthy normal weight male and otherwise healthy overweight or obese female volunteers, thus the PK and PD CV effects of adrenaline doses other than 500 µg, and in other populations, cannot be ascertained from the current study. Although sex and BMI may not be risk factors for anaphylactic reaction and responses to treatment, future research could aim to address some of these shortcomings by assessing normal weight women and overweight or obese men. Although not a limitation of the current study, which assessed the bioavailability and CV effects of adrenaline administered by Anapen 500 µg auto-injector in healthy volunteers, it is noteworthy that recent data from the European Anaphylaxis Register show a clear discrepancy between international recommendations for the use of adrenaline in the first-line treatment of anaphylaxis and actual clinical practice, calling for wider discussion of the reasons for the treatment gap.[18]

In conclusion, a single 500 µg adrenaline injection using the Anapen auto-injector in healthy normal weight male and otherwise normal, overweight and obese female volunteers produced rapid increases in circulating adrenaline levels which were accompanied by significant increases in SBP and HR. These responses occurred irrespective of whether the injection was intramuscular or subcutaneous and, in all cases, treatment was well tolerated.

13652125, 2023, 3, Downloaded from https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15545 by Cochrane France, Wiley Online Library on [26/02/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

ACKNOWLEDGEMENTS

Under the direction of the authors, medical writing and editorial support was provided by Robert A. Furlong, PhD, and David P. Figgitt, PhD, ISMPP CMPP, Content Ed Net, with funding from Bioprojet Pharma, Paris, France.

COMPETING INTEREST

T. Duvauchelle has received consultancy fees from Phaster1 and is employed by Bioprojet. P. Robert is employed by Bioprojet. Y. Donazzolo has received consultancy fees and fees for participation in review activities and payment for writing/reviewing the manuscript from Eurofins Optimed. S. Loyau and B. Orlandini have received consultancy fees, fees for participation in review activities and payment for writing/reviewing the manuscript from PhinC Development. P. Lehert has received consultancy fees from Bioprojet. J.-M. Lecomte and J.-C. Schwartz are employed by, and have stock/stock options in, Bioprojet.

AUTHOR CONTRIBUTIONS

T.D. and P.R. contributed to study conception and design. Y.D. contributed to the acquisition of data. T.D., P.R., S.L. and P.L. contributed to data analysis. T.D. and P.R. were involved in drafting the manuscript. All authors critically revised the manuscript for important intellectual content. All authors read and approved the final manuscript. The authors confirm that the Principal Investigator for this paper is Yves Donazzolo and that he had direct clinical responsibility for subjects.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Thierry Duvauchelle https://orcid.org/0000-0002-4762-588X

REFERENCES

1. Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. *N Engl J Med*. 1992;327(6):380-384. doi:10.1056/NEJM199208063270603
2. Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. *Clin Exp Allergy*. 2000;30(8):1144-1150. doi:10.1046/j.1365-2222.2000.00864.x
3. Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. *J Allergy Clin Immunol*. 2001;107(1):191-193. doi:10.1067/mai.2001.112031
4. Worm M, Moneret-Vautrin A, Scherer K, et al. First European data from the network of severe allergic reactions (NORA). *Allergy*. 2014;69(10):1397-1404. doi:10.1111/all.12475
5. Turner PJ, Gowland MH, Sharma V, et al. Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012. *J Allergy Clin Immunol*. 2015;135(4):956-63.e1. doi:10.1016/j.jaci.2014.10.021
6. Boyce JA, Assa'ad A, Burks AW, et al. Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report. *J Allergy Clin Immunol*. 2010;126(6):1105-1118. doi:10.1016/j.jaci.2010.10.008
7. Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. *J Allergy Clin Immunol*. 2010;126(3):477-480. doi:10.1016/j.jaci.2010.06.022
8. Muraro A, Roberts G, Worm M, et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. *Allergy*. 2014;69(8):1026-1045. doi:10.1111/all.12437
9. Simons FE, Ebisawa M, Sanchez-Borges M, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. *World Allergy Organ J*. 2015;8(1):32. doi:10.1186/s40413-015-0080-1
10. Simons FER, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. *J Allergy Clin Immunol*. 2001;108(5):871-873. doi:10.1067/mai.2001.119409
11. Sheikh A, Simons FE, Barbour V, Worth A. Adrenaline auto-injectors for the treatment of anaphylaxis with and without cardiovascular collapse in the community. *Cochrane Database Syst Rev*. 2012;(8):CD008935. doi:10.1002/14651858.CD008935.pub2
12. Fromer L. Prevention of anaphylaxis: The role of the epinephrine auto-injector. *Am J Med*. 2016;129(12):1244-1250. doi:10.1016/j.amjmed.2016.07.018
13. Duvauchelle T, Robert P, Donazzolo Y, et al. Bioavailability and cardiovascular effects of adrenaline administered by anapen autoinjector in healthy volunteers. *J Allergy Clin Immunol Pract*. 2018;6(4):1257-1263. doi:10.1016/j.jaip.2017.09.021
14. World Medical Association. WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. 2013. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/
15. Breuer C, Wachall B, Gerbeth K, Abdel-Tawab M, Fuhr U. Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler. *Eur J Clin Pharmacol*. 2013;69(6):1303-1310. doi:10.1007/s00228-012-1465-5
16. Worm M, Nguyen D, Rackley R, Muraro A, Du Toit G, Lawrence T. Epinephrine delivery via EpiPen® Auto-Injector or manual syringe across participants with a wide range of skin-to-muscle distances. *Clin Transl Allergy*. 2020;10(1):21. doi:10.1186/s13601-020-00326-x
17. Wood JP, Traub SJ, Lipinski C. Safety of epinephrine for anaphylaxis in the emergency setting. *World J Emerg Med*. 2013;4(4):245-251. doi:10.5847/wjem.j.issn.1920-8642.2013.04.001
18. Grabenhenrich LB, Dölle S, Ruëff F, et al. Epinephrine in severe allergic reactions: The European Anaphylaxis Register. *J Allergy Clin Immunol Pract*. 2018;6(6):1898-1906.e1. doi:10.1016/j.jaip.2018.02.026

How to cite this article: Duvauchelle T, Robert P, Donazzolo Y, et al. Bioavailability and cardiovascular effects of adrenaline administered by Anapen 500 μg auto-injector in healthy volunteers. *Br J Clin Pharmacol*. 2023;89(3):1012-1019. doi:10.1111/bcp.15545

13652125, 2023, 3, Downloaded from https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15545 by Cochrane France, Wiley Online Library on [26/02/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License